Mirum's Revenue Surge and Raised Outlook Spark an 11% Rally — But Can a Money-Losing Drugmaker Sustain the Momentum?

Shares of Mirum Pharmaceuticals jumped 11.1% to $96.73 after the rare-liver-disease specialist posted third-quarter sales that outran Wall Street expectations and lifted its full-year revenue forecast. The move rewards investors who held through a sluggish stretch — the stock had drifted near $85 for weeks — but the question now is whether accelerating sales can outpace ballooning costs.

• Sales Grew 40%, and Nine Months Already Match All of Last Year

Q3 net product sales hit $185.7 million, up 40% year-over-year, beating the consensus estimate of $183.92 million. More striking: the first nine months of 2026 generated roughly $522 million in product sales — already equal to full-year 2025 revenue.

Management raised its 2026 guidance to $715–$720 million, up from the prior $680–$700 million range. That implies a fourth quarter north of $193 million, a pace that would need sustained momentum from its lead drug for cholestatic liver diseases, which drove the bulk of the quarter's growth.

• The Loss Column Is Getting Bigger, Not Smaller

Mirum swung from a $2.9 million net profit in Q3 2025 to a $40.8 million net loss this quarter, driven by an 88% surge in operating expenses to $245.5 million.

Research spending alone ran about $94 million, roughly half of quarterly revenue , fueled by late-stage clinical trials and large one-time charges tied to the acquisition of Bluejay Therapeutics.

Management said it is on track to become cash-flow positive in 2027 , but investors must take that timeline on faith.

• Wall Street Analysts Are Broadly Bullish

Cantor Fitzgerald raised its price target to $160 , Citigroup lifted its target to $184 , and HC Wainwright bumped its target to $202.

Of 15 covering analysts, 14 rate the stock a Buy or equivalent, with an average target around $150 — still well above today's price. The consensus implies confidence that Mirum's pipeline of treatments for rare liver and bone diseases will eventually convert revenue growth into profits.

• A $500 Million Cash Cushion Buys Time

Mirum ended Q3 with $500.5 million in unrestricted cash and investments , and burned only about $4 million in operating cash during the quarter. That near-breakeven cash burn — despite the GAAP loss — suggests the commercial business is largely self-funding while R&D spending peaks. If trial readouts deliver over the next two quarters, today's rally could look like just the opening act.